Table 1.

Summary of prospective clinical trials that have demonstrated survival benefit for HPV-related OPSCC.

Trial	Design	Result
ECOG 2399	Phase II trial of locoregionally advanced HNC treated with two cycles of IC (paclitaxel + carboplatin) followed by concomitant weekly paclitaxel and standard fractionation RT	HPV-related OPSCC had better OS (p = 0.004) and PFS (p = 0.05)
RTOG 0129	Phase III RCT of locoregionally advanced OPSCC comparing standard-fractionation RT vs. accelerated-fractionation RT, each concurrent with cisplatin	HPV-related OPSCC had better 3-year OS (82.4% vs. 57.1%, p < 0.001)
RTOG 0522	Phase III RCT of locoregionally advanced HNC treated with concurrent RT with cisplatin, with or without cetuximab	HPV-related OPSCC had better 3-year PFS (72.8% vs. 49.2%, p < 0.001) and 3-year OS (85.6% vs. 60.1%, p < 0.001)
TROG 02.02	Phase III trial of locoregionally advanced HNC RCT with concurrent RT with cisplatin, with or without tirapazamine	HPV-related OPSCC had better 2-year PFS (87% vs. 72%, p = 0.003) and OS (91% vs. 74%, p = 0.004)
TAX324	Phase III RCT of locoregionally advanced HNC testing IC with either TPF or PF	HPV-related OPSCC had better 5-year OS (82% vs. 35%, p < 0.0001)
DAHANCA 6&7	Phase III RCT of locoregionally advanced HNC treated with accelerated vs. standard RT	HPV-related HNC had better 5-year OS (62% vs. 47%); did not perform analysis of OP-only

Abbreviations: ECOG = Eastern Cooperative Oncology Group; RTOG = Radiation Therapy Oncology Group; TROG = Trans-Tasman Radiation Oncology Group; HNC = head and neck cancer; IC = induction chemotherapy; RT = radiation therapy; CRT = chemoradiation therapy; RCT = randomized clinical trial; OS = overall survival; PFS = progression-free survival; TPF = docetaxel, cisplatin, 5-fluorouracil.